Effects of Satureja Khuzestanica Jamzad on type 2 diabetes

Effects of Satureja Khuzestanica Jamzad supplementation on inflammatory and antioxcidant markers in type 2 diabetes patients: a randomized controlled clinical trial study(RCT)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191106045348N1

Enrollment

Registered

2021-02-22

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: Intervention group: The subjects in the intervention group will be given a capsule containing 500 mg of Satureja Khuzestanica. They should take a 500 mg capsule dai

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 65 years Age between 20 and 65 years Willingness to cooperate Completing the informed consent form

Exclusion criteria

Exclusion criteria: Insulin injection Pregnant and lactating women Weight loss diet Inflammatory disease Taking corticosteroids Omega 3 consumption Women who are planning to become pregnant Allergy to safflower

Design outcomes

Primary

Measure	Time frame
CRP. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;CAT. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;SOD. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;GPX. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;TAC. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;GR. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;IL-6. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.	—

Measure

Time frame

CRP. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;CAT. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;SOD. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;GPX. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;TAC. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;GR. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.;IL-6. Timepoint: Before and 12 weeks after beginning intervention. Method of measurement: Serum levels Measuring.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmaryam bordbar

Khoram-Abad University of Medical Sciences

maryambordbar758@gmail.com+98 66 3342 1216

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026